Oncology Drugs - Indonesia | Statista Market Forecast

In Indonesia, the Oncology Drugs market is expected to experience significant growth in the coming years.
By 2024, the projected revenue is estimated to reach US$557.40m.
This indicates a promising market potential for oncology drugs in the country.
Furthermore, the market is anticipated to maintain a steady annual growth rate of 7.33% from 2024 to 2029.
This consistent growth trajectory is projected to result in a robust market volume of US$794.10m by 2029.
When compared on a global scale, it is worth noting that United States is expected to generate the highest revenue in the Oncology Drugs market.
In 2024 alone, the revenue United States is projected to reach a staggering US$103.90bn.
This highlights the significant market dominance and potential of the United States in the field of oncology drugs.
The demand for innovative oncology drugs in Indonesia is growing rapidly, driven by an increasing prevalence of cancer cases and a growing awareness of advanced treatment options.

Definition:
The Oncology Drugs market covers drugs to treat cancer, including chemotherapy and immunotherapy. These therapies are used for solid tumors and hematologic cancer. The medications in this market are mainly physician-administered drugs.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Bristol-Myers Squibb, Roche, Merck & Co, Novartis, Johnson & Johnson

Treatment for different types of cancer, including skin cancer, leukemia, lymphoma, and multiple myeloma
Chemotherapeutic agents
Immuno-oncology drugs
Oncology orphan drugs

Radiation therapy
Medical devices

The demand for oncology drugs in Indonesia has been steadily increasing over the past few years.

Customer preferences: Indonesian customers are becoming more aware of the importance of early detection and treatment of cancer. As a result, they are more willing to invest in expensive oncology drugs that offer higher chances of successful treatment. Additionally, there is a growing preference for targeted therapies that are more effective and have fewer side effects.

Trends in the market: One of the major trends in the Indonesian oncology drugs market is the increasing number of cancer cases. This has led to a rise in demand for chemotherapy drugs, immunotherapy drugs, and targeted therapies. Additionally, there is a growing trend towards the use of biosimilars, which are cheaper alternatives to branded oncology drugs. The Indonesian government has also been taking steps to improve access to oncology drugs by increasing the number of public hospitals and clinics that offer cancer treatment.

Local special circumstances: Indonesia is the fourth most populous country in the world, with a large and growing middle class. This has led to an increase in demand for healthcare services, including oncology drugs. However, there are still significant challenges in the Indonesian healthcare system, such as limited access to healthcare in rural areas and a shortage of trained healthcare professionals.

Underlying macroeconomic factors: The Indonesian economy has been growing steadily over the past few years, with a GDP growth rate of around 5% in 2019. This has led to an increase in disposable income and a growing middle class, which has contributed to the demand for healthcare services. Additionally, the Indonesian government has been investing in infrastructure and healthcare, which has helped to improve access to oncology drugs. However, there are still challenges in the Indonesian healthcare system, such as limited access to healthcare in rural areas and a shortage of trained healthcare professionals.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Cancer is one of the leading causes of death worldwide, with lung cancer alone ranked the sixth leading cause of death in 2021. Cancer, also known as malignant tumors and neoplasms, is the result of interactions between personal genetic factors and external agents causing abnormal transformations of cells into tumors over time. As the global population has increased in age, the incidence of new cancer cases has also risen, contributing to a higher number of deaths each year. In 2022, nearly 10 million deaths were caused by cancer worldwide- a number which is expected to reach over 15 million by 2040.